Payment overview · 2025
General Payments
$11,275.40
118 reported records · 23 companies
Healthcare provider profile · identity verified
Anthony A Patsy, DO
Allopathic & Osteopathic Physicians|Family Medicine · OWOSSO, MI · NPI 1760652655
Verified facts
What the public records show
CMS Open Payments records show Anthony A Patsy, DO received $11,275.40 in general payments during 2025 across 118 reported records.
Amgen Inc. accounted for 83.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Gemtesa, Jardiance, Mounjaro, Otezla, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Auvelity by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $9,463.47 | 83.9% | 25 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $205.29 | 1.8% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $196.02 | 1.7% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $188.95 | 1.7% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $155.12 | 1.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.81 | 1.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $144.60 | 1.3% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.66 | 1.3% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $128.43 | 1.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $111.41 | 1.0% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.98 | 0.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.72 | 0.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $41.03 | 0.4% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.26 | 0.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.64 | 0.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.53 | 0.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.02 | 0.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.10 | 0.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.98 | 0.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.05 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.57 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.76 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,200.00 | 7 |
| Food and Beverage | $1,948.54 | 108 |
| Education | $126.86 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $9,400.69 | 21 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $196.02 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $188.95 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $173.03 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.66 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $141.66 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $131.78 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $129.68 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $128.43 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $126.14 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $110.45 | 16 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.50 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.50 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.98 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.94 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $62.78 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $56.61 | 3 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $56.61 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $56.61 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.72 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $41.03 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 270 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 110 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 194 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
270 | 72 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
107 | 25 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
194 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
270 | 72 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 778 | 220 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 745 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 590 | 173 |
| Lisinopril | Lisinopril | 493 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 453 | 141 |
| Losartan Potassium | Losartan Potassium | 451 | 132 |
| Metformin Hcl | Metformin Hcl | 419 | 121 |
| Omeprazole | Omeprazole | 382 | 126 |
| Gabapentin | Gabapentin | 330 | 73 |
| Potassium Chloride | Potassium Chloride | 314 | 110 |
| Tramadol Hcl | Tramadol Hcl | 274 | 47 |
| Eliquis | Apixaban | 270 | 72 |
| Simvastatin | Simvastatin | 264 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 98 |
| Atenolol | Atenolol | 247 | 66 |
| Alprazolam | Alprazolam | 238 | 50 |
| Ezetimibe | Ezetimibe | 208 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 60 |
| Ozempic | Semaglutide | 194 | 37 |
| Famotidine | Famotidine | 183 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 50 |
| Trazodone Hcl | Trazodone Hcl | 173 | 48 |
| Furosemide | Furosemide | 171 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 169 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 48 |
| Ibuprofen | Ibuprofen | 161 | 49 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 161 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 49 |
| Allopurinol | Allopurinol | 141 | 42 |
| Montelukast Sodium | Montelukast Sodium | 135 | 42 |
| Repatha Sureclick | Evolocumab | 135 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 41 |
| Cephalexin | Cephalexin | 128 | 96 |
| Lorazepam | Lorazepam | 121 | 23 |
| Carvedilol | Carvedilol | 118 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 36 |
| Mounjaro | Tirzepatide | 110 | 24 |
| Prednisone | Prednisone | 110 | 52 |
| Sertraline Hcl | Sertraline Hcl | 109 | 37 |
| Trulicity | Dulaglutide | 107 | 25 |
| Clonazepam | Clonazepam | 106 | 17 |
| Fluconazole | Fluconazole | 105 | 56 |
| Bumetanide | Bumetanide | 103 | 34 |
| Methadone Hcl | Methadone Hcl | 98 | 12 |
| Januvia | Sitagliptin Phosphate | 93 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 91 | 27 |
| Enalapril Maleate | Enalapril Maleate | 91 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 25 |
| Jardiance | Empagliflozin | 88 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 30 |
| Pregabalin | Pregabalin | 87 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 23 |
| Meloxicam | Meloxicam | 83 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 22 |
| Warfarin Sodium | Warfarin Sodium | 83 | 26 |
| Vascepa | Icosapent Ethyl | 78 | 14 |
| Buspirone Hcl | Buspirone Hcl | 77 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 23 |
| Baclofen | Baclofen | 76 | 33 |
| Glimepiride | Glimepiride | 74 | 21 |
| Metformin Hcl Er | Metformin Hcl | 72 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 13 |
| Alendronate Sodium | Alendronate Sodium | 68 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 18 |
| Diazepam | Diazepam | 66 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 48 |
| Myrbetriq | Mirabegron | 65 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | suppressed |
| Amoxicillin | Amoxicillin | 60 | 48 |
| Morphine Sulfate Er | Morphine Sulfate | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | 16 |
| Xarelto | Rivaroxaban | 58 | 12 |
| Celecoxib | Celecoxib | 57 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 15 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 51 | 13 |
| Ketoconazole | Ketoconazole | 51 | 30 |
| Spironolactone | Spironolactone | 51 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 47 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 16 |
| Glipizide | Glipizide | 44 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 15 |
| Mirtazapine | Mirtazapine | 43 | 12 |
| Terazosin Hcl | Terazosin Hcl | 43 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 11 |
| Finasteride | Finasteride | 42 | suppressed |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Gemtesa | Vibegron | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 36 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Testosterone | Testosterone | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Colchicine | Colchicine | 30 | 18 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Naproxen | Naproxen | 28 | 11 |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 14 |
| Nitroglycerin | Nitroglycerin | 26 | 15 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Nystatin | Nystatin | 24 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Azithromycin | Azithromycin | 23 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Mirabegron Er | Mirabegron | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tobramycin | Tobramycin | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Dupixent Pen | Dupilumab | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,275.40 · 118 records | Amgen Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, AREXVY, Auvelity, BREZTRI, Belbuca, CAPLYTA, COMIRNATY, ELIQUIS, EOHILIA, EVENITY, FANAPT, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, JOURNAVX, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error